1385P Phase II study of neoadjuvant camrelizumab combined with chemoradiation for locally advanced proximal gastric cancer (Neo-PLANET, NCT03631615)

Tang, Z-Q.; Wang, Y.; Liu, D.; Yu, Yangli; Cui, Yu-Hong; Tang, Cheng; Sun, Jian; Zhang, Q.; Ji, Yuan; Gf, Ma; Shen, Zhiqiang; Fl, Liu; Shen, Kaiyuan; Wang, X.; Ts, Liu; Sun, Ying

doi:10.1016/j.annonc.2021.08.1494

Cited by 6 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Research on adjuvant chemotherapy for GC is ongoing and is expected to further improve the survival rates of patients with GC [ 37 38 39 40 ]. Although these findings support the importance of adjuvant chemotherapy, there is no consensus regarding the duration of adjuvant chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Different Number of XELOX or SOX Chemotherapy Cycles After D2 Resection for Stage III Gastric Cancer

Zhang

Meng

et al. 2022

J Gastric Cancer

View full text Add to dashboard Cite

Purpose We aimed to explore whether the prognosis of patients treated with capecitabine and oxaliplatin (XELOX) or S-1 and oxaliplatin (SOX) regimens who received fewer cycles of chemotherapy after D2 radical resection for gastric cancer (GC) would be non-inferior to that of patients who received the standard number of cycles of chemotherapy. Materials and Methods Data on patients who received XELOX or SOX chemotherapy after undergoing D2 radical resection at Harbin Medical University Cancer Hospital between January 2011 and May 2016 were collected. Results In patients who received 4, 6, and 8 cycles of chemotherapy, the 5-year overall survival (OS) rates were 59.4%, 64.8%, and 62.7%, respectively. Compared to patients who received 4 cycles of chemotherapy, those who received 6 cycles (hazard ratio [HR], 0.882; 95% confidence interval [CI], 0.599–1.299; P=0.52) or 8 cycles (HR, 0.882; 95% CI, 0.533–1.458; P=0.62) of chemotherapy did not exhibit significantly prolonged OS. The 3-year disease-free survival (DFS) rate of patients who received 4, 6, and 8 cycles of chemotherapy was 62.1%, 67.2%, and 60.8%, respectively. Compared to patients who received 4 cycles of chemotherapy, those who received 6 cycles (HR, 0.835; 95% CI, 0.572–1.221; P=0.35) or 8 cycles (HR, 0.972; 95% CI, 0.606–1.558; P=0.91) of chemotherapy did not show significantly prolonged DFS. However, the 3-year DFS and 5-year OS rates of patients who received 6 cycles of chemotherapy appeared to be superior to those of patients who received 4 and 8 cycles of chemotherapy. Conclusions For patients with stage III GC, 4 to 6 cycles of XELOX or SOX chemotherapy may be a favorable option. This study provides a rationale for further randomized clinical trials.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of Different Number of XELOX or SOX Chemotherapy Cycles After D2 Resection for Stage III Gastric Cancer

Zhang

Meng

et al. 2022

J Gastric Cancer

View full text Add to dashboard Cite

show abstract

“…The original search identified a total of 602 publications, and the study retrieval process is depicted in Figure 1. Twenty studies met the inclusion criteria, including a total number of 753 patients, were included in this meta-analysis (17,(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38). Of these, 15 studies reported that patients received neoadjuvant immunotherapy combined with chemotherapy, which our meta-analysis mainly focused on.…”

Section: Resultsmentioning

confidence: 99%

“…Several studies have illustrated that the addition of radiotherapy ( 28 , 30 ) or anti-VEGF drugs ( 20 , 29 ) improved the effectiveness of neoadjuvant therapy. Our study reported that, compared with the addition of radiotherapy or anti-VEGF drugs with single neoadjuvant immunochemotherapy, the combination with radiotherapy did improve MPR rate but had a higher incidence of TRAEs.…”

Section: Discussionmentioning

confidence: 99%

Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

BackgroundImmune checkpoint inhibitors (ICIs) have shown promising prospects in locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) immunotherapy, but their efficacy in neoadjuvant settings remains unclear. This study aimed to assess the efficacy and safety of integrating programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors into neoadjuvant chemotherapy (NACT) of GC/GEJC treatment.MethodsPubMed, Cochrane Library, Embase, ClinicalTrials.gov, and main oncology conference databases were systematically searched up to 19 November 2022, and randomized controlled trials (RCTs) and cohort studies that evaluated the efficacy and safety of PD-1/PD-L1 inhibitors plus NACT were included. The main outcomes were pathological complete response (pCR), major pathological response (MPR), R0 resection rate, and treatment-related adverse events (TRAEs).ResultsA total of 753 patients from 20 prospective studies were included in this meta-analysis. The pooled pCR and MPR rates from studies reporting were 21.7% [95% confidence interval (CI), 18.1%–25.5%] and 44.0% (95% CI, 34.1%–53.8%), respectively. The pooled incidence rate of total TRAEs was 89.1% (95% CI, 82.7%–94.3%), and the incidence rate of grade 3 to 4 TRAEs was 34.4% (95% CI, 17.8%–66.5%). The pooled R0 resection rate was reported to be 98.9% (95% CI, 97.0%–99.9%). Subgroup analysis has not found significant differences in efficacy and safety among different PD-1/PD-L1 inhibitors. Moreover, the efficacy in patients with positive PD-L1 expression (combined positive score ≥1) was comparable with that in the entire study population [pCR, 22.5% vs. 21.2% (p > 0.05); MPR, 48.6% vs. 43.7% (p > 0.05)].ConclusionThis systematic review and meta-analysis found that PD-1/PD-L1 inhibitors combined with NACT for locally advanced GC/GEJC were well tolerated and may confer therapeutic advantages. The integration of ICIs into NACT has shown the potential for application in any PD-L1 expression population.

show abstract

“…Patients were required to receive four cycles of XELOX adjuvant chemotherapy within 4–6 weeks postoperatively. Results indicated that camrelizumab combined with radiation and chemotherapy was an effective treatment for patients with locally advanced GC, ORR was 93.3%, the pathological complete response (pCR) rate was 33.3%, the primary endpoint of the phase I trial, and the phase II trial was ongoing ( 70 , 71 ). Neoadjuvant concurrent chemoradiotherapy followed by surgery in patients with locally advanced esophageal, or GEJA, who received durvalumab showed an excellent survival benefit with 2-year recurrence-free survival and OS of 55.5% and 67.4%, respectively ( 72 ).…”

Section: Icis Combined With Other Treatments Of Advanced Gcmentioning

confidence: 99%

Recent advances in the progress of immune checkpoint inhibitors in the treatment of advanced gastric cancer: A review

Shen

Wang

2022

Front. Oncol.

View full text Add to dashboard Cite

Most patients with advanced gastric cancer were treated with palliative therapy, which had a poor curative effect and a short survival time. In recent years, the clinical research of immune checkpoint inhibitors in advanced gastric cancer has made a breakthrough and has become an important treatment for advanced gastric cancer. The modes of immune checkpoint inhibitors in the treatment of advanced gastric cancer include single drug, combined chemotherapy, radiotherapy, and multiple immune drug combination therapy, among which combination therapy shows better clinical efficacy, and a large number of trials are currently exploring more effective combination therapy programs. In this paper, the new clinical research progress of immune checkpoint inhibitors in the treatment of advanced gastric cancer is reviewed, with an emphasis on combination therapy.

show abstract

1385P Phase II study of neoadjuvant camrelizumab combined with chemoradiation for locally advanced proximal gastric cancer (Neo-PLANET, NCT03631615)

Cited by 6 publications

References 0 publications

Efficacy of Different Number of XELOX or SOX Chemotherapy Cycles After D2 Resection for Stage III Gastric Cancer

Efficacy of Different Number of XELOX or SOX Chemotherapy Cycles After D2 Resection for Stage III Gastric Cancer

Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis

Recent advances in the progress of immune checkpoint inhibitors in the treatment of advanced gastric cancer: A review

Contact Info

Product

Resources

About